Search the web
Welcome, Guest
[Sign Out, My Account]

Wednesday, April 1 2015 6:43pm ET - U.S. Markets Closed.
Industry Center
Industry Center > > Actelion Ltd. Company Profile
More On This Industry
· Summary
· News
· Leaders & Laggards
· Company Index
·Industry Browser
Top Industries
·Aerospace/Defense - Major Diversified
·Auto Manufacturers - Major
·Business Software & Services
·Chemicals - Major Diversified
·Communication Equipment
·Diversified Computer Systems
·Diversified Investments
·Drug Manufacturers - Major
·Electric Utilities
·Food - Major Diversified
·Industrial Metals & Minerals
·Major Airlines
·Major Integrated Oil & Gas
·Money Center Banks
·Property & Casualty Insurance
·Semiconductor - Broad Line
·Telecom Services - Domestic
Complete Industry List...
Need more? Get unbiased, in-depth information on public and private companies worldwide.
Actelion Ltd. Company Profile
Drugmaker Actelion is anything but neutral in its fight against life-threatening diseases. The Swiss drugmaker develops and markets small molecule drugs in a number of therapeutic areas, including cardiovascular disease, oncology, and autoimmune disease. Actelion has several products on the market: It sells Tracleer worldwide and Ventavis in the US as treatments for pulmonary arterial hypertension (PAH), a serious disease characterized by high blood pressure in the arteries connecting the heart and lungs. The company also markets Zavesca, which treats an inherited metabolic disorder called Gaucher disease. Actelion has sales and marketing subsidiaries in more than 25 countries around the world.
Headlines for Actelion Ltd.
Actelion says wins Japanese approval for heart and lung drug
- Thu Mar 26
Activist investor Elliott seeks to shake up Alliance Trust
- Mon Mar 16
Alliance Trust rejects Elliott's move to appoint directors
- Fri Mar 20
Alliance Trust, Elliott's clash over directors escalates
- Fri Mar 20
Independent panel to FDA backs Kythera's injection to reduce double chin
- Mon Mar 9
Alliance invokes Elliott track record in appeal against board shake-up
- Thu Mar 26
Contact Information
Address: Gewerbestrasse 16
4123 Allschwil, Baselland, Switzerland
Financial Highlights
Fiscal Year End:December
Revenue (2013):2005.40 M
Revenue Growth (1 yr):6.00%
Employees (2013):2,396
Employee Growth (1 yr):(-1.50%)
Key People
Chairman: Jean-Pierre (JP) Garnier
CEO: Jean-Paul Clozel
EVP and COO: Otto Schwarz
Industry Information
Top Competitors
Genzyme Corporation
Gilead Sciences, Inc. (gild)
United Therapeutics Corporation (uthr)

Copyright © 2015 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Industry information © 2015 Morningstar, Inc. All Rights Reserved. Company information © 2015 Capital IQ All Rights Reserved. Quotes and other information supplied by independent providers identified on the Yahoo Finance partner page. S&P 500 index provided by Comstock. All rights reserved. Top-Ranked Analyst information © 1999-2015, StarMine Corp. All rights reserved. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, Morningstar, CSI and exchanges) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Yahoo site, a user agrees not to redistribute the information found therein.

Questions or Comments?